Publicaciones en colaboración con investigadores/as de Universidad de Salamanca (74)

2022

  1. Aportación de la farmacocinética al tratamiento con fenobarbital: aplicación a algunos casos clínicos

    Farmajournal, Vol. 7, Núm. 1, pp. 83-91

  2. Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients

    Pharmaceutics, Vol. 14, Núm. 4

2020

  1. Farmacocinética poblacional de fenitoína en pacientes adultos

    Farmajournal, Vol. 5, Núm. 2, pp. 15-26

  2. Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy

    European Journal of Pharmaceutical Sciences, Vol. 153

2018

  1. Age as a Factor of Differentiation in Predictive Models of Valproic Acid Pharmacokinetics

    1st Global Congress of Pharmacy Faculties. Innovation in Pharmacy: Advances and Perspectives. September 24-28th, Salamanca, Spain 2018

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

  2. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 955-956, Núm. 1, pp. 93-97

2013

  1. Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43

2011

  1. Desarrollo y aplicación de recursos audiovisuales docentes en el área de farmacia y tecnología farmacéutica

    Primeras Jornadas de Innovación Docente en la Universidad de Salamanca

  2. Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  3. Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324

  4. Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

    Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582

2010

  1. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

    Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157

  2. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

2009

  1. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798

  2. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2008

  1. Correspondence Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

    AIDS

  2. Efavirenz–rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

    AIDS, Vol. 22, Núm. 18, pp. 2549-2551

  3. Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy

    Therapeutic Drug Monitoring, Vol. 30, Núm. 4, pp. 483-489